Andrea Comba1,2,3, Patrick J Dunn1,2,3, Anna E Argento1,2,3, Padma Kadiyala1,2,3, Maria Ventosa1,2,3, Priti Patel1,2,3, Daniel B Zamler1,2,3, Felipe J Núñez1,2,3, Lili Zhao4, Maria G Castro1,2,3, Pedro R Lowenstein1. 1. Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan. 2. Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, Michigan. 3. Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan. 4. Department of Biostatistics, University of Michigan Medical School, Ann Arbor, Michigan.
Abstract
BACKGROUND: High-grade gliomas are aggressive and immunosuppressive brain tumors. Molecular mechanisms that regulate the inhibitory immune tumor microenvironment (TME) and glioma progression remain poorly understood. Fyn tyrosine kinase is a downstream target of the oncogenic receptor tyrosine kinase pathway and is overexpressed in human gliomas. Fyn's role in vivo in glioma growth remains unknown. We investigated whether Fyn regulates glioma initiation, growth and invasion. METHODS: We evaluated the role of Fyn using genetically engineered mouse glioma models (GEMMs). We also generated Fyn knockdown stem cells to induce gliomas in immune-competent and immune-deficient mice (nonobese diabetic severe combined immunodeficient gamma mice [NSG], CD8-/-, CD4-/-). We analyzed molecular mechanism by RNA sequencing and bioinformatics analysis. Flow cytometry was used to characterize immune cellular infiltrates in the Fyn knockdown glioma TME. RESULTS: We demonstrate that Fyn knockdown in diverse immune-competent GEMMs of glioma reduced tumor progression and significantly increased survival. Gene ontology (GO) analysis of differentially expressed genes in wild-type versus Fyn knockdown gliomas showed enrichment of GOs related to immune reactivity. However, in NSG and CD8-/- and CD4-/- immune-deficient mice, Fyn knockdown gliomas failed to show differences in survival. These data suggest that the expression of Fyn in glioma cells reduces antiglioma immune activation. Examination of glioma immune infiltrates by flow cytometry displayed reduction in the amount and activity of immune suppressive myeloid derived cells in the Fyn glioma TME. CONCLUSIONS: Gliomas employ Fyn mediated mechanisms to enhance immune suppression and promote tumor progression. We propose that Fyn inhibition within glioma cells could improve the efficacy of antiglioma immunotherapies.
BACKGROUND: High-grade gliomas are aggressive and immunosuppressive brain tumors. Molecular mechanisms that regulate the inhibitory immune tumor microenvironment (TME) and glioma progression remain poorly understood. Fyn tyrosine kinase is a downstream target of the oncogenic receptor tyrosine kinase pathway and is overexpressed in human gliomas. Fyn's role in vivo in glioma growth remains unknown. We investigated whether Fyn regulates glioma initiation, growth and invasion. METHODS: We evaluated the role of Fyn using genetically engineered mouse glioma models (GEMMs). We also generated Fyn knockdown stem cells to induce gliomas in immune-competent and immune-deficient mice (nonobese diabetic severe combined immunodeficient gamma mice [NSG], CD8-/-, CD4-/-). We analyzed molecular mechanism by RNA sequencing and bioinformatics analysis. Flow cytometry was used to characterize immune cellular infiltrates in the Fyn knockdown glioma TME. RESULTS: We demonstrate that Fyn knockdown in diverse immune-competent GEMMs of glioma reduced tumor progression and significantly increased survival. Gene ontology (GO) analysis of differentially expressed genes in wild-type versus Fyn knockdown gliomas showed enrichment of GOs related to immune reactivity. However, in NSG and CD8-/- and CD4-/- immune-deficient mice, Fyn knockdown gliomas failed to show differences in survival. These data suggest that the expression of Fyn in glioma cells reduces antiglioma immune activation. Examination of glioma immune infiltrates by flow cytometry displayed reduction in the amount and activity of immune suppressive myeloid derived cells in the Fyn glioma TME. CONCLUSIONS: Gliomas employ Fyn mediated mechanisms to enhance immune suppression and promote tumor progression. We propose that Fyn inhibition within glioma cells could improve the efficacy of antiglioma immunotherapies.
Authors: Kan V Lu; Shaojun Zhu; Anna Cvrljevic; Tiffany T Huang; Shawn Sarkaria; David Ahkavan; Julie Dang; Eduard B Dinca; Seema B Plaisier; Isaac Oderberg; Yohan Lee; Zugen Chen; Jeremy S Caldwell; Yongmin Xie; Joseph A Loo; David Seligson; Arnab Chakravari; Francis Y Lee; Roberto Weinmann; Timothy F Cloughesy; Stanley F Nelson; Gabriele Bergers; Thomas Graeber; Frank B Furnari; C David James; Webster K Cavenee; Terrance G Johns; Paul S Mischel Journal: Cancer Res Date: 2009-08-18 Impact factor: 12.701
Authors: Andrea Majoros; Ekaterini Platanitis; Elisabeth Kernbauer-Hölzl; Felix Rosebrock; Mathias Müller; Thomas Decker Journal: Front Immunol Date: 2017-01-26 Impact factor: 7.561
Authors: Xiaosi Han; Wenbin Zhang; Xiuhua Yang; Crystal G Wheeler; Catherine P Langford; Lu Wu; Natalia Filippova; Gregory K Friedman; Qiang Ding; Hassan M Fathallah-Shaykh; G Yancey Gillespie; L Burt Nabors Journal: Int J Oncol Date: 2014-05-09 Impact factor: 5.650
Authors: Andrea Comba; Syed M Faisal; Patrick J Dunn; Anna E Argento; Todd C Hollon; Wajd N Al-Holou; Maria Luisa Varela; Daniel B Zamler; Gunnar L Quass; Pierre F Apostolides; Clifford Abel; Christine E Brown; Phillip E Kish; Alon Kahana; Celina G Kleer; Sebastien Motsch; Maria G Castro; Pedro R Lowenstein Journal: Nat Commun Date: 2022-06-24 Impact factor: 17.694
Authors: Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro Journal: Front Oncol Date: 2021-06-08 Impact factor: 5.738
Authors: Kesavan R Arya; Ramachandran P Bharath Chand; Chandran S Abhinand; Achuthsankar S Nair; Oommen V Oommen; Perumana R Sudhakaran Journal: Biomolecules Date: 2021-03-09